Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05299658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05299658 · ClinicalTrials.gov record · last posted 2025-12-19

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Name: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS — clinical trial record (NCT05299658)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorClene Nanomedicine

Started2021-11-13

View on ClinicalTrials.gov ↗

Record status

This record was last updated December 19, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2022-03-17; most recent amendment 2025-12-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT05299658
Lead Sponsor	Clene Nanomedicine
Conditions	Amyotrophic Lateral Sclerosis
Enrollment	40 participants
Start Date	2021-11-13
Primary Completion	2026-06 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-19